NG-348
/ Akamis Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Phase 1 first-in-human study of NG-348 – an oncolytic adenovirus expressing CD80 and anti-CD3 scFv in patients with advanced epithelial tumors
(SITC 2026)
- No abstract available
Clinical • First-in-human • Metastases • Oncolytic virus • P1 data • Oncology • Solid Tumor • CD80
1 to 1
Of
1
Go to page
1